Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 7 for:    inspiron
Previous Study | Return to List | Next Study

Post-marketing Registry of Inspiron Sirolimus Eluting Coronary Stent (Inspiron RL II)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03263260
Recruitment Status : Recruiting
First Posted : August 28, 2017
Last Update Posted : March 17, 2020
Sponsor:
Information provided by (Responsible Party):
Scitech Produtos Medicos Ltda

Brief Summary:
Post-marketing, prospective, multicentric, non-randomized registry to evaluate the safety and efficacy of Inspiron Sirolimus Eluting Coronary Stent at the treatment of "real-world" patients.

Condition or disease Intervention/treatment
Coronary Artery Disease Device: implant

Detailed Description:

Up to 5.0000 patients with native coronary arteries lesions with diameter between 2.5 and 4.0 mm and 34 mm of length treated solely with the Inspiron Sirolimus Eluting Coronary Stent.

Stent implantation should be performed according to the Instructions for Use and according to the local practice. It is recommended that ECG and cardiac enzymes are collected before and after procedure. Dual anti-platelet therapy is recommended for at least 6 months after procedure.

Patients will be followed at 30 days, 1 and 2 years after procedure.

Layout table for study information
Study Type : Observational [Patient Registry]
Estimated Enrollment : 5000 participants
Observational Model: Other
Time Perspective: Prospective
Target Follow-Up Duration: 24 Months
Official Title: Prospective, Multicentric, Post-marketing Registry of Inspiron Sirolimus Eluting Coronary Stent for Treatment of Patients With Native Coronary Artery Lesions (Inspiron Real Life II)
Actual Study Start Date : June 2, 2017
Estimated Primary Completion Date : December 30, 2021
Estimated Study Completion Date : December 30, 2022

Resource links provided by the National Library of Medicine

Drug Information available for: Sirolimus

Group/Cohort Intervention/treatment
implanted patients
Patients with native coronary artery lesions with diameter between 2.5 and 4.0 and 34 mm of length treated only with the Inspiron Sirolimus eluting Stent
Device: implant
coronary stent implantation




Primary Outcome Measures :
  1. Major Adverse Cardiac Events Rate [ Time Frame: 12 months ]
    Cardiac Death, MI, Target Lesion Revascularization and Stent Thrombosis


Secondary Outcome Measures :
  1. Target Vessel and Lesion Revascularization Rates [ Time Frame: 24 months ]
    Target Vessel and Lesion Revascularization

  2. Stent Thrombosis Rate [ Time Frame: 24 months ]
    Stent Thrombosis



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patients older than 18 years submitted to implant of the Inspiron Sirolimus Eluting Stent in native coronary arteries
Criteria

Inclusion Criteria:

  • alll patients that have been treated with the Inspiron Sirolimus Eluting Stent older and 18 years

Exclusion Criteria:

  • Safein Vein or Left Internal Mammary artery Grafts

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03263260


Contacts
Layout table for location contacts
Contact: Erico Rossi +55 62 3625-5000

Locations
Layout table for location information
Brazil
União Brasileira de Educação e Assistência - Hospital São Lucas da PUC - RS Recruiting
Porto Alegre, Rio Grande Do Sul, Brazil, 90.619-900
Contact: Paulo Caramori, Medicine       caramori@cardiarte.com.br   
Principal Investigator: Paulo Caramori, Medicine         
Sponsors and Collaborators
Scitech Produtos Medicos Ltda
Additional Information:

Layout table for additonal information
Responsible Party: Scitech Produtos Medicos Ltda
ClinicalTrials.gov Identifier: NCT03263260    
Other Study ID Numbers: Inspiron RL II
First Posted: August 28, 2017    Key Record Dates
Last Update Posted: March 17, 2020
Last Verified: March 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
Keywords provided by Scitech Produtos Medicos Ltda:
stent, DES, Inspiron
Additional relevant MeSH terms:
Layout table for MeSH terms
Coronary Artery Disease
Coronary Disease
Myocardial Ischemia
Heart Diseases
Cardiovascular Diseases
Arteriosclerosis
Arterial Occlusive Diseases
Vascular Diseases